Works by Huang, Dingzhi

Results: 45
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2024, v. 15, n. 5, p. 419, doi. 10.1111/1759-7714.15209
    By:
    • Lin, Gen;
    • Wang, Zhijie;
    • Chu, Qian;
    • Hu, Yi;
    • Huang, Dingzhi;
    • Wang, Jun;
    • Yang, Fan;
    • Zhong, Wenzhao;
    • Zhou, Chengzhi;
    • Zhu, Bo;
    • Ai, Xinghao;
    • Cao, Baoshan;
    • Cao, Yabing;
    • Chen, Mingqiu;
    • Chen, Xiaohui;
    • Chu, Tianqing;
    • Duan, Jianchun;
    • Fan, Yun;
    • Fang, Yong;
    • Feng, Shuitu
    Publication type:
    Article
    11
    12
    13
    14
    15
    16

    Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

    Published in:
    Therapeutic Advances in Medical Oncology, 2023, v. 15, p. 1, doi. 10.1177/17588359231189429
    By:
    • Lu, Shun;
    • Zheng, Xiangqian;
    • Sun, Yuping;
    • Huang, Dingzhi;
    • Wu, Lin;
    • Ji, Qinghai;
    • Zhou, Chengzhi;
    • Zhou, Jianying;
    • Guo, Ye;
    • Ge, Minghua;
    • Ding, Ding;
    • Shao, Jingxin;
    • Zhang, Wanli;
    • Gao, Ming;
    • Cheng, Ying
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-024-02115-5
    By:
    • Chen, Zhiwei;
    • Chen, Jianhua;
    • Huang, Dingzhi;
    • Zhang, Wei;
    • Wu, Lin;
    • Yi, Tienan;
    • Wang, Qiming;
    • Han, Liang;
    • Tan, Liping;
    • Li, Yinyin;
    • Zhang, Zhihong;
    • Li, Na;
    • li, Jie;
    • Zhang, Tongmei;
    • Hu, Ying;
    • Sun, Hongmei;
    • Wu, Youhua;
    • He, Zhiyong;
    • Yang, Runxiang;
    • Cheng, Peng
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

    Published in:
    Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01823-w
    By:
    • Zhang, Linlin;
    • Wang, Liuchun;
    • Wang, Jingya;
    • Chen, Jinliang;
    • Meng, Zhaoting;
    • Liu, Zhujun;
    • Jiang, Xiangli;
    • Wang, Xinyue;
    • Huang, Chun;
    • Chen, Peng;
    • Liang, Yan;
    • Jiang, Richeng;
    • Wang, Jing;
    • Zhong, Diansheng;
    • Shang, Yanhong;
    • Zhang, Yan;
    • Zhang, Cuiying;
    • Huang, Dingzhi
    Publication type:
    Article
    44
    45